Gilead Sciences, Inc. (GILD) Shares Sold by Perigon Wealth Management LLC
Perigon Wealth Management LLC reduced its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 70,498 shares of the biopharmaceutical company’s stock after selling 904 shares during the period. Gilead Sciences comprises about 1.1% of Perigon Wealth Management LLC’s holdings, making the stock its 20th largest holding. Perigon Wealth Management LLC’s holdings in Gilead Sciences were worth $4,990,000 at the end of the most recent quarter.
A number of other institutional investors have also made changes to their positions in GILD. Intl Fcstone Inc. purchased a new stake in shares of Gilead Sciences during the 2nd quarter worth about $1,110,000. Griffin Asset Management Inc. purchased a new stake in shares of Gilead Sciences during the 2nd quarter worth about $1,151,000. Gs Investments Inc. purchased a new stake in shares of Gilead Sciences during the 2nd quarter worth about $577,000. Paradigm Financial Advisors LLC raised its stake in shares of Gilead Sciences by 0.3% during the 2nd quarter. Paradigm Financial Advisors LLC now owns 8,723 shares of the biopharmaceutical company’s stock worth $617,000 after purchasing an additional 26 shares in the last quarter. Finally, RNC Capital Management LLC raised its stake in shares of Gilead Sciences by 1.4% during the 2nd quarter. RNC Capital Management LLC now owns 83,702 shares of the biopharmaceutical company’s stock worth $5,924,000 after purchasing an additional 1,185 shares in the last quarter. 76.23% of the stock is owned by hedge funds and other institutional investors.
A number of research firms have recently weighed in on GILD. BidaskClub raised Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Thursday. Mizuho reaffirmed a “buy” rating on shares of Gilead Sciences in a research note on Friday, September 29th. Maxim Group reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Thursday, October 19th. Berenberg Bank reaffirmed a “buy” rating and set a $86.00 price target (up from $79.00) on shares of Gilead Sciences in a research note on Sunday, August 20th. Finally, Credit Suisse Group reaffirmed a “buy” rating and set a $82.00 price target on shares of Gilead Sciences in a research note on Thursday, December 7th. One research analyst has rated the stock with a sell rating, twelve have given a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Gilead Sciences presently has a consensus rating of “Buy” and an average target price of $85.11.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.13 by $0.14. The firm had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The company’s revenue was down 13.2% on a year-over-year basis. During the same quarter last year, the firm posted $2.75 EPS. research analysts predict that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be issued a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.75%. The ex-dividend date of this dividend is Thursday, December 14th. Gilead Sciences’s dividend payout ratio (DPR) is currently 23.69%.
In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $74.98, for a total value of $5,498,508.34. Following the sale, the insider now owns 3,070,099 shares of the company’s stock, valued at approximately $230,196,023.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Gregg H. Alton sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $74.64, for a total value of $1,119,600.00. Following the completion of the sale, the executive vice president now directly owns 70,988 shares in the company, valued at approximately $5,298,544.32. The disclosure for this sale can be found here. Insiders sold a total of 494,999 shares of company stock worth $37,404,139 in the last ninety days. Insiders own 1.30% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/16/gilead-sciences-inc-gild-shares-sold-by-perigon-wealth-management-llc.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Stock Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related stocks with our FREE daily email newsletter.